Showing all 4 results

  • Dapagliflozin & Metformin Extended Release Tablets (10/500 mg)

    Dapagliflozin & Metformin Extended Release Tablets are a fixed-dose combination used to manage type 2 diabetes mellitus in adults. Dapagliflozin, an SGLT2 inhibitor, lowers blood sugar by increasing glucose excretion through the urine, while Metformin, a biguanide, reduces glucose production in the liver and improves insulin sensitivity. Together, they offer effective glycemic control, support weight loss, and provide cardiovascular benefits. This extended-release formulation enhances tolerability, especially for gastrointestinal side effects linked to metformin.

    Read more

  • Dapagliflozin 10mg, Sitagliptin 100mg & Metformin Hydrochloride (ER) 1000mg Tablets

    Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin Hydrochloride (Extended-Release) 1000 mg Tablets are an oral, fixed-dose combination used to manage type 2 diabetes mellitus in adults. This triple therapy combines three agents with complementary mechanisms. Dapagliflozin, an SGLT2 inhibitor, lowers blood glucose by promoting urinary glucose excretion. Sitagliptin, a DPP-4 inhibitor, enhances glucose-dependent insulin secretion and reduces glucagon levels. Metformin (ER), a biguanide, decreases hepatic glucose production and improves insulin sensitivity.

    Read more

  • Dapagliflozin And Metformin Extended Release Tablets

    Dapagliflozin and Metformin Extended-Release Tablets are a fixed-dose oral combination used to manage Type 2 Diabetes Mellitus (T2DM). The tablet combines dapagliflozin, an SGLT2 inhibitor, and metformin, a biguanide antihyperglycemic agent in extended-release form. Together, they lower blood glucose by reducing glucose reabsorption in the kidneys (dapagliflozin) and decreasing hepatic glucose production while improving insulin sensitivity (metformin).

    Read more

  • Dapagliflozin Tablets 10mg

    Dapagliflozin Tablets 10 mg are oral antidiabetic medications belonging to the class of SGLT2 inhibitors. They help lower blood sugar levels in adults with type 2 diabetes mellitus by preventing glucose reabsorption in the kidneys, causing excess glucose to be excreted in the urine. In addition to improving glycemic control, dapagliflozin also offers cardiovascular and renal benefits, such as reducing the risk of heart failure hospitalization and slowing the progression of chronic kidney disease, even in non-diabetic patients.

    Read more